Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Publication
- Publication Type
Articles 1 - 9 of 9
Full-Text Articles in Life Sciences
The European Patent Office And The European Patent: An Open Avenue For Biotechnologists And "Living Inventions", Katrina Mcclatchey
The European Patent Office And The European Patent: An Open Avenue For Biotechnologists And "Living Inventions", Katrina Mcclatchey
Oklahoma Journal of Law and Technology
No abstract provided.
Agricultural Biogechnology: United States Statutory Law, Jo Lynn Jeter
Agricultural Biogechnology: United States Statutory Law, Jo Lynn Jeter
Oklahoma Journal of Law and Technology
No abstract provided.
The International Treaty On Plant Genetic Resources For Food And Agriculture: Friend Of The International Farmer, Steven M. Ruby
The International Treaty On Plant Genetic Resources For Food And Agriculture: Friend Of The International Farmer, Steven M. Ruby
Oklahoma Journal of Law and Technology
No abstract provided.
The Effect Of The "Onco-Mouse" Decisions On The Exception To Patentability For "Animal Varieties" Under The European Patent Convention, Katrina Mcclatchey
The Effect Of The "Onco-Mouse" Decisions On The Exception To Patentability For "Animal Varieties" Under The European Patent Convention, Katrina Mcclatchey
Oklahoma Journal of Law and Technology
No abstract provided.
Emerging Drivers And Business Models For Equipment Reuse And Remanufacturing In The Us Lessons From The Biotech Industry-2017.Pdf, Vesela R. Veleva, Gavin Bodkin
Emerging Drivers And Business Models For Equipment Reuse And Remanufacturing In The Us Lessons From The Biotech Industry-2017.Pdf, Vesela R. Veleva, Gavin Bodkin
Vesela Veleva
Do The Evolution: The Effect Of Ksr V. Teleflex On Biotechnology, Josh Harrison
Do The Evolution: The Effect Of Ksr V. Teleflex On Biotechnology, Josh Harrison
Oklahoma Journal of Law and Technology
No abstract provided.
Metabolic Comparison Of Wild-Type And Transgenic Synechocystis Pcc 6803 Cyanobacteria, Ian A. Mcluckey, John A. Morgan, Joel Yu King Hing
Metabolic Comparison Of Wild-Type And Transgenic Synechocystis Pcc 6803 Cyanobacteria, Ian A. Mcluckey, John A. Morgan, Joel Yu King Hing
The Summer Undergraduate Research Fellowship (SURF) Symposium
The Calvin-Benson (CBB) cycle is an essential part of nature. This phenomenon allows carbon molecules in carbon dioxide from the atmosphere to be converted into useful energy in the form of sugars. Cyanobacteria are single-celled organisms capable of utilizing energy from sunlight to drive this cycle and are also readily engineered. In hopes of improving this cycle, we compared a wild-type version of the Synechocystis PCC6803 cyanobacteria to an engineered version overexpressing the enzyme FBA (fructose-biphosphate aldolase), called 70 glpX, to deduce how the overexpressing strain is able to be more photosynthetically efficient. To do this, comparative metabolomics were done …
Establishing A Lung Model For Evaluation Of Engineered Lung Microbiome Therapies, Kathryn F. Atherton, Stephen Miloro, Jenna Rickus
Establishing A Lung Model For Evaluation Of Engineered Lung Microbiome Therapies, Kathryn F. Atherton, Stephen Miloro, Jenna Rickus
The Summer Undergraduate Research Fellowship (SURF) Symposium
Benzene, a toxin and carcinogen found in air polluted by cigarette smoke, car exhaust, and industrial processes, is associated with the development of leukemia and lymphoma. Other than avoiding exposure, there is no current method to deter the effects of benzene. One potential strategy to prevent these effects is to engineer the bacteria of the human lung microbiome to degrade benzene. To evaluate this novel approach, we must verify that the bacteria remain viable within the lung microenvironment. To do so, lungs were harvested from rats and swabbed to determine the contents of the original lung microbiome. Then green fluorescent …
Re-Framing Biotechnology Regulation, Alison Peck
Re-Framing Biotechnology Regulation, Alison Peck
Law Faculty Scholarship
Biotechnology is about to spill the banks of federal regulation. New genetic engineering techniques like CRISPR-Cas9 promise revolutionary breakthroughs in medicine, agriculture, and public health-but those techniques would not be regulated under the terms of the Coordinated Framework for Regulation of Biotechnology. This revolutionary moment in biotechnology offers an opportunity to correct the flaws in the framework, which was hastily patched together at the advent of the technology. The framework has never captured all relevant technologies, has never satisfied the public that risk is being effectively managed, and has never been accessible to small companies and publicly-funded labs that increasingly …